Zymeworks (ZYME) has released an update.
Zymeworks Inc. has announced FDA clearance for an investigational new drug, ZW171, targeting mesothelin-expressing cancers with a novel bispecific antibody. This advancement signifies progress in Zymeworks’ ‘5 by 5’ strategy, with clinical trials set to commence in 2024. ZW171 aims to improve cancer treatment effectiveness and safety by selective tumor targeting, reducing side effects, and enhancing T-cell mediated tumor cell killing.
For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.